A study analysing cost effectiveness and efficacy of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan
Latest Information Update: 27 Oct 2021
At a glance
- Drugs Romosozumab (Primary) ; Alendronic acid; Teriparatide
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- 27 Oct 2021 New trial record
- 01 Oct 2021 Results published in the Osteoporosis International